DDReg pharma

DELIVER BETTER DATA TO ENSURE FASTER APPROVAL
DDReg Pharma

Author name: development

EMA's expedited pathways

How EMA’s Expedited Pathways and Scientific Advice Are Shaping Drug Approvals

At the DIA 2024 Global Annual Meeting in San Diego, key officials from the European Medicines Agency (EMA) shed light on the various expedited approval pathways available for sponsors of innovative drugs and Advanced Therapy Medicinal Products (ATMPs). This blog post explores the insights shared by EMA officials, delves into the various expedited pathways available, […]

How EMA’s Expedited Pathways and Scientific Advice Are Shaping Drug Approvals Read More »

Managing Director of DDReg chosen as finalist for CPhI Pharma Awards 2024

DDReg is incredibly proud to announce that our Founder and Managing Director, Ms. Neeti Pant, has been chosen as a finalist by the prestigious CPhI panel for the “Woman of the Year” award at the CPhI Pharma Awards 2024, being held in Milan. This recognition is a testament to her visionary leadership, dedication to innovation,

Managing Director of DDReg chosen as finalist for CPhI Pharma Awards 2024 Read More »

Japan’s Approach to eCTD V4.0

In the pursuit of global harmonization in pharmaceutical regulation, Japan which is renowned for its meticulous standards and innovative spirit, has taken a significant step by implementing the Electronic Common Technical Document (eCTD) v4.0. This move aligns Japan with international standards set by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human

Japan’s Approach to eCTD V4.0 Read More »

Does the FDA need a new approval pathway?

The accelerated approval pathway is established to expedite the availability of drugs for serious or life-threatening conditions. It allows the FDA to approve treatments based on surrogate or intermediate endpoints before confirmatory studies are completed. This pathway has been instrumental in advancing treatments for rare diseases and unmet medical needs, relying on a balance between

Does the FDA need a new approval pathway? Read More »

Regulatory Framework for Software and Artificial Intelligence as Medical Device

The convergence of healthcare with technology has led to giant innovations, one of the most significant being the use of software and artificial intelligence (AI) as medical devices. Such developments have been called Software as a Medical Device (SaMD) by many and have wide applicability in transforming the diagnosis, treatment, and care of patients medically.

Regulatory Framework for Software and Artificial Intelligence as Medical Device Read More »

Specifications for In Vitro Diagnostic Devices

In vitro diagnostic medical devices (IVD devices) are an integral part of the healthcare system. They are typically used to analyze samples that are collected from the human body (i.e., saliva, blood, tissue, and urine) and help in diagnosing, screening, and monitoring various conditions. IVD devices are subjected to different regulations that specify different requirements

Specifications for In Vitro Diagnostic Devices Read More »

Faster Access to Clinical Trial Information in Europe

Improving access to clinical trial information is critical in order to advance medical research while also ensuring patient safety. Enhanced transparency can not only accelerate innovation but also empower various stakeholders to make appropriate and informed decisions in order to progress medical research forward. The European Medicines Agency (EMA) has introduced several improvements in the

Faster Access to Clinical Trial Information in Europe Read More »

The Use of EDDO to Ensure Drug Delivery Function

When it comes to ensuring the safety and effectiveness of medical devices intended to deliver drugs, understanding Essential Drug Delivery Outputs (EDDO) is important. The advent of drug-device combination products has necessitated the development of robust guidelines to ensure safety, efficacy, and performance. One such crucial aspect of these combination products is the Essential Drug

The Use of EDDO to Ensure Drug Delivery Function Read More »

Emerging Drug Safety Technology Program

Pharmacovigilance practices are associated with several challenges related to collection of safety data, processing, assessment, and volume of patient safety data. As technological disruptors- like artificial intelligence (AI)- develop, so do the solutions to tackle such challenges. This leads to more efficient pharmacovigilance (PV) systems and processes that ultimately enhance drug safety monitoring. Whether it

Emerging Drug Safety Technology Program Read More »